BeyondSpring Q2 net loss $1.8M; ASCO data show 58% 24-month OS in post-ICI NSCLC

BeyondSpring Inc.

Q2 2026 net loss $1.8M vs $1.9M YoY; cash and short-term investments $6.5M at June 30, 2026.
ASCO 2026 Phase 2 (n=47): median PFS 7.0 mo, ORR 18.2%, DCR 79.5%, 24-month OS 58.0%.
Leadership effective July 1, 2026: Min Qiu CEO, Jen Majeti Vice Chairman, Na Li CFO.
DUBLIN-4 planned confirmatory Phase 3: 442 patients, non-squamous EGFR-wild-type NSCLC post-ICI.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.